TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6416805

Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin ointment (2 cm/m2 body surface)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of 2% nitroglycerin ointment and 50 mg atenolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31738179

Group type: EXPERIMENTAL
Intervention: Familiarization with nine predefined app quality principles
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Subsequent reassessment with 25 key questions
Number of subjects: 441
Study: 30986326

Group type: EXPERIMENTAL
Intervention: Rotary NiTi to size 20, .04 taper with syringe and needle (SNI)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Rotary NiTi to size 20, .04 taper with ultrasonically activated irrigation (UAI)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Rotary NiTi to size 40, .04 taper with syringe and needle (SNI)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Rotary NiTi to size 40, .04 taper with ultrasonically activated irrigation (UAI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (untreated canals)
Number of subjects: 96
Study: 27714530

Group type: EXPERIMENTAL
Intervention: Ginger (500 mg) twice daily for 5 days starting on the first day of the second AC cycle
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo twice daily for 5 days starting on the first day of the second AC cycle
Number of subjects: 34
Study: 26045831

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg intravenous injection for 20 min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 50
Study: 23555741

Group type: EXPERIMENTAL
Intervention: 2 doses of IIV
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LAIV then IIV
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IIV then LAIV
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LAIV-IIV administration
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 26

Group type: COMPARATOR
Intervention: Homologous and heterologous prime boost immunization
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Heterologous prime-boost vaccination
Number of subjects: 26
Study: 21651947

Group type: EXPERIMENTAL
Intervention: SII HibP(RO) vaccine manufactured at industrial scale
Number of subjects: 204

Group type: COMPARATOR
Intervention: SII HibP(RO) vaccine manufactured at small scale
Number of subjects: 204
Study: 19384770

Group type: EXPERIMENTAL
Intervention: Vitrectomy with cautious removal of vitreous cortex in group A
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vitrectomy without removal of vitreous cortex in groups B and C
Number of subjects: 22
Study: 16707631

Group type: EXPERIMENTAL
Intervention: Custom foot orthoses
Number of subjects: 154

Group type: COMPARATOR
Intervention: Simple sham insoles
Number of subjects: 154
Study: 15560804

Group type: EXPERIMENTAL
Intervention: Miswak chewing stick
Number of subjects: 15

Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 15
Study: 11213940

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide infusion at 10 microg/kg/min for 24 to 120 hours after a bolus of 0.6 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide infusion
Number of subjects: 32
Study: 9105824

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasmapheresis (PRP), performed before incision
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group, managed without pheresis
Number of subjects: 40
Study: 7713200

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2967665

Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide polysulphate (MPS) cream applied twice daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cream base (control) applied twice daily
Number of subjects: 33
Study: 28974520

Group type: EXPERIMENTAL
Intervention: torcetrapib plus atorvastatin
Number of subjects: 249

Group type: COMPARATOR
Intervention: atorvastatin only
Number of subjects: 249
Study: 27780197

Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg/kg buccal 40% dextrose gel
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Any dose of dextrose gel
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Dextrose gel
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 416
Study: 24332674

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 712

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 712
Study: 23991577

Group type: EXPERIMENTAL
Intervention: Gow-Gates technique of inferior alveolar nerve block
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional technique of inferior alveolar nerve block
Number of subjects: 32
Study: 21926374

Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia
Number of subjects: 70

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 70
Study: 18585493

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study: 17150115

Group type: EXPERIMENTAL
Intervention: Free breakfast served at the beginning of each school day for 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no breakfast served)
Number of subjects: 0
Study: 12931275

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.3 U/kg 125I‐insulin glargine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: NPH insulin (0.3 U/kg 125I‐NPH insulin)
Number of subjects: 14
Study: 10959779

Group type: EXPERIMENTAL
Intervention: Powered toothbrush prototype (B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Marketed powered toothbrush (A)
Number of subjects: 62
Study: 8617707

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg daily for 10 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carbamazepine (200 mg once daily for 2 days, then every 12 hours)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carbamazepine plus Sertraline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Carbamazepine plus Placebo
Number of subjects: 14
Study: 1451644

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 136

Group type: COMPARATOR
Intervention: Pefloxacin
Number of subjects: 136
Study: 44553

Group type: EXPERIMENTAL
Intervention: 0.3% tiodonium chloride rinse
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31571176

Group type: EXPERIMENTAL
Intervention: Intraventricular alteplase injections (n=251)
Number of subjects: 5686

Group type: COMPARATOR
Intervention: Saline (placebo) injections (n=249)
Number of subjects: 5686
Study: 30824955

Group type: EXPERIMENTAL
Intervention: Doripenem (1.0 g every 8 h)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Meropenem (1.0 g every 8 h)
Number of subjects: 133
Study: 27667533

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 162

Group type: COMPARATOR
Intervention: Bupivacaine HCl (control)
Number of subjects: 162
Study: 26039902

Group type: EXPERIMENTAL
Intervention: Regular Contact
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Optional Contact
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: No Contact
Number of subjects: 490

Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 490
Study: 23639302

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional expressions (angry expression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual and real human heads
Number of subjects: 0
Study: 21324135

Group type: EXPERIMENTAL
Intervention: Low dose olanzapine LAI (150 mg/2 weeks)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Medium dose olanzapine LAI (405 mg/4 weeks)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: High dose olanzapine LAI (300 mg/2 weeks)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Low dose olanzapine LAI
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Medium dose olanzapine LAI
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: High dose olanzapine LAI
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: All doses of olanzapine LAI
Number of subjects: 599
Study: 18852332

Group type: EXPERIMENTAL
Intervention: Oral glucose (28 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 10
Study: 16764344

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 232
Study: 16311764

Group type: EXPERIMENTAL
Intervention: .VO(2max) at 300 m
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: .VO(2max) at 2,800 m
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Performance time to exhaustion at constant velocity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arterial haemoglobin oxygen saturation (SpO2) at test cessation
Number of subjects: 8
Study: 12791116

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (500 micro g.kg-1 i.v. ketamine preincision and a ketamine infusion at 4 micro g.kg-1 min-1 postoperatively)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ketamine bolus (500 micro g.kg-1 i.v. ketamine preincision and a saline infusion postoperatively)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (saline infusion postoperatively)
Number of subjects: 75
Study: 10434830

Group type: EXPERIMENTAL
Intervention: Iontophoretically applied lidocaine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham (control) group
Number of subjects: 2
Study: 7672970

Group type: EXPERIMENTAL
Intervention: Passy-Muir Speaking Valve (PMV)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Open (unvalved) tube
Number of subjects: 11
Study: 2212460

Group type: EXPERIMENTAL
Intervention: Near retinoscopy technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cycloplegic refraction
Number of subjects: 20
Study: 7241426

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0
Study: 29785836

Group type: EXPERIMENTAL
Intervention: Psychosocial support intervention
Number of subjects: 173
Study: 29354965

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control acupuncture
Number of subjects: 0
Study: 26604719

Group type: EXPERIMENTAL
Intervention: DANCE (virtual reality video game dancing)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: MEMORY (treadmill walking with simultaneous verbal memory training)
Number of subjects: 89

Group type: COMPARATOR
Intervention: PHYS (treadmill walking)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Global effects (all groups)
Number of subjects: 89
Study: 23569309

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with paclitaxel/gemcitabine (PG)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 231
Study: 21165924

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 201
Study: 18201644

Group type: EXPERIMENTAL
Intervention: Hand-held computer (PDA) intervention with monitoring and feedback
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard information control arm (age-appropriate written physical activity educational materials)
Number of subjects: 37
Study: 15975756

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 57
Study: 12512035

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for 1 year
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for 2 additional years
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for 3 years
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients without YMDD variants
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients with YMDD variants
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients with YMDD variants for >2 years
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bridging fibrosis improvement
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cirrhosis improvement
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Progression to cirrhosis
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Progression to bridging fibrosis
Number of subjects: 63
Study: 10488603

Group type: EXPERIMENTAL
Intervention: Neurolinguistic Programming (NLP) intervention applied to the experimental group (EG) consisting of 23 children; 15 sessions of NLP.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CG) with 22 children with no intervention.
Number of subjects: 45
Study: 8899084

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 604

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 604
Study: 1904989

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin therapy at a dose of 400 mg per kilogram every three weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No immune globulin therapy (Control)
Number of subjects: 0
Study: 7046774

Group type: EXPERIMENTAL
Intervention: labetalol monotherapy (329 mg daily for 12 weeks)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: labetalol combined with diuretics (374 mg daily for 12 weeks)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: labetalol monotherapy (260 mg daily for 6 months or longer)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: labetalol combined with diuretics (450 mg daily for 6 months or longer)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: labetalol for phaeochromocytoma
Number of subjects: 178
Study: 31280536

Group type: EXPERIMENTAL
Intervention: PiCCO monitoring rehydration group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Routine rehydration group
Number of subjects: 65
Study: 28013069

Group type: EXPERIMENTAL
Intervention: 10-week internet-based multifaceted cognitive bias modification training (CBM)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 10-week school-based cognitive behavioral group training (CBT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 240
Study: 26255456

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg i.v. dissolved in 10 ml 0.9% NaCl
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl 10 mg)
Number of subjects: 72
Study: 24310521

Group type: EXPERIMENTAL
Intervention: Visible collaterals
Number of subjects: 5412

Group type: EXPERIMENTAL
Intervention: Patients undergoing PCI with visible collaterals
Number of subjects: 5412
Study: 21692846

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 30
Study: 19650984

Group type: EXPERIMENTAL
Intervention: Clonidine transdermal patch
Number of subjects: 119

Group type: COMPARATOR
Intervention: Oral haloperidol
Number of subjects: 119
Study: 17727931

Group type: EXPERIMENTAL
Intervention: Total mesometrial resection (TMMR) without adjuvant radiation
Number of subjects: 163
Study: 15291907

Group type: EXPERIMENTAL
Intervention: Oral desensitization with increasing doses of cow's milk starting from 0.06 mg of CM proteins
Number of subjects: 21
Study: 11292409

Group type: EXPERIMENTAL
Intervention: Ganciclovir implant plus oral ganciclovir (1 gm three times daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intravenous cidofovir (5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ganciclovir implant plus oral ganciclovir
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intravenous cidofovir
Number of subjects: 61
Study: 9030876

Group type: EXPERIMENTAL
Intervention: IFN-alpha (rhIFN-alpha2b; 5 x 10(6) U/m2)
Number of subjects: 8
Study: 8292845

Group type: EXPERIMENTAL
Intervention: 100 IU/day salmon calcitonin intramuscularly for 2 weeks starting on admission
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study: 3103479

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isoflurane and Halothane
Number of subjects: 100
Study: 30762450

Group type: EXPERIMENTAL
Intervention: Presence of prostate atrophy (P.A.) in baseline prostate biopsies
Number of subjects: 136

Group type: COMPARATOR
Intervention: Absence of prostate atrophy (P.A.) in baseline prostate biopsies
Number of subjects: 136
Study: 28107143

Group type: EXPERIMENTAL
Intervention: Clarithromycin 5 mg/kg daily for 4 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 58
Study: 24520943

Group type: EXPERIMENTAL
Intervention: High-spatial-resolution (HR, 0.23-mm) coronary CT angiography
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard spatial resolution (SR, 0.625-mm) coronary CT angiography
Number of subjects: 184
Study: 22585166

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4560
Study: 20921465

Group type: EXPERIMENTAL
Intervention: Panitumumab-FOLFOX4
Number of subjects: 1183

Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 1183
Study: 18294337

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) + Sulfadoxine/Pyrimethamine (SDx/PYR) combination
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Higher dose of CQ + SDx/PYR
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Full-strength CQ + SDx/PYR combination
Number of subjects: 86
Study: 16186278

Group type: EXPERIMENTAL
Intervention: Non-mydriatic photography
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: Mydriatic photography
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: Presence of obvious central cataract
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: Presence of early cataract
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: No cataract
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: Other pathologies
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: Pupil diameter
Number of subjects: 3650
Study: 14608559

Group type: EXPERIMENTAL
Intervention: Droperidol and acupressure bands
Number of subjects: 143

Group type: COMPARATOR
Intervention: Droperidol and placebo bands
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo drug and acupressure bands
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo drug and placebo bands
Number of subjects: 143
Study: 10513645

Group type: EXPERIMENTAL
Intervention: Nelfinavir, zidovudine, and lamivudine
Number of subjects: 0
Study: 7745195

Group type: EXPERIMENTAL
Intervention: Ice applied to subcutaneous heparin injection sites
Number of subjects: 70
Study: 2174657

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Kallidin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: [des-Arg9]bradykinin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 16
Study: 7114515

Group type: EXPERIMENTAL
Intervention: Cimetidine (therapy group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (therapy group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cimetidine (preventive group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (preventive group)
Number of subjects: 40
Study: 29461414

Group type: EXPERIMENTAL
Intervention: On-court fitness test (ST)
Number of subjects: 8
Study: 28844621

Group type: EXPERIMENTAL
Intervention: Unedited risk statement
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Serious and actionable risks only
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Disclosure indicating that not all risks are presented
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1500
Study: 26814004

Group type: EXPERIMENTAL
Intervention: Preoperative educational intervention (booklet, individual teaching session, follow-up support call)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard care (usual teaching)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Preoperative educational intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 143
Study: 25332474

Group type: EXPERIMENTAL
Intervention: Dairy diet (3 servings/d: 375 mL low-fat milk, 175 g low-fat yogurt, 30 g regular-fat cheddar cheese)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control diet (energy-matched: fruit juice, vegetable juice, cashews, and 1 cookie)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dairy diet
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 112
Study: 23053790

Group type: EXPERIMENTAL
Intervention: Total testosterone (ng/mL)
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: SHBG (nmol/L)
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Free estradiol (fg/mL)
Number of subjects: 898
Study: 20173425

Group type: EXPERIMENTAL
Intervention: Distributed form of constraint‐induced therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 13
Study: 18809812

Group type: COMPARATOR
Intervention: Healthy diet (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 25% CR from baseline energy requirements (CR group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 25% energy deficit by a combination of CR and increased aerobic exercise (CR + EX group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD group)
Number of subjects: 46
Study: 16162401

Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Haloperidol (2-40 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 31
Study: 12389342

Group type: EXPERIMENTAL
Intervention: Natural remedy ('Chick‐Chack') containing coconut oil, anise oil, and ylang ylang oil; applied three times at 5-day intervals for 15 minutes each time.
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control pediculicide spray containing permethrin, malathion, piperonyl butoxide, isododecane, and propellant gas; applied twice for 10 minutes with a 10-day interval between applications.
Number of subjects: 119